Connect with us

Featured

Argentum 47 Inc (OTCMKTS: ARGQ) Heating Up and Getting Noticed as Co Executes Legally Binding LOI to Acquire the Data Source (UK) Limited

Published

on

Argentum 47 Inc (OTCMKTS: ARGQ) is making a powerful move northbound after the Company executed a legally binding letter of intent to acquire UK based company, The Data Source (UK) Limited (https://www.thedatasource.co.uk/), a data driven B2B and B2C solutions provider utilizing artificial intelligence with lead generation, automation, and analytics. With offices in London, UK, the Data Source is currently honing in on the North America, where they are already making inroads into the real estate and capital markets sectors, offering services including business intelligence and research, demographic, market data and public data. The Data Source already has an established customer base in the UK including American Express, Bacardi, Vodafone, Money Super Market and Revolt. The basis of the proposed transaction is for Argentum 47 Inc. to acquire 100% of The Data Source (UK) Limited by way of management relinquishing their personal right, title and interest in a combination of stock that constitutes precisely 51% of the voting stock of Argentum on fully diluted and converted basis (“Control Block”). Additional shares of Argentum 47, Inc. Common Stock will be issued to the TDS shareholders post-closing. 

Reverse merger stocks can be more explosive than biotech’s when the incoming Company has real value (such as the Data Source) but is undiscovered to investors and many RM stocks, we have covered on this website have gone from pennies to dollars including one that went from subs to multi-dollars. ARGQ has a very favorable stock structure with 735,116,983 shares outstanding with half restricted leaving a float of just 361,890,060 free trading shares. Authorized is set at 950 million and ARGQ trades at a total market valuation of $5,770,668. ARGQ is quickly getting noticed by some big players in small caps who are heavily accumulating at current levels. They are looking for a break over $0.016 and a TSNP style reverse merger move. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Argentum 47 Inc (OTCMKTS: ARGQ) is a clean “pink current” reverse merger stock that has just executed a legally binding letter of intent to acquire UK based company, The Data Source (UK) Limited, a data driven B2B and B2C solutions provider utilizing artificial intelligence with lead generation, automation, and analytics. TDS provides its clients with world class data with the aim of becoming a one-stop-shop for all things data. Reuters, Vodafone, Revolut, Honda and American Express are just a few of the companies they have worked with.  The next stage of development for TDS is within North America, where they are already making inroads into the real estate and capital markets sectors, offering services including business intelligence and research, demographic, market data and public data.  

https://twitter.com/nikspicks1122/status/1508801697111592961

To Find out the inside Scoop on ARGQ Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

ARGQ

ARGQ reverse merger is here. The Company just executed a legally binding letter of intent to acquire UK based company, The Data Source (UK) Limited (“TDS”). TDS is a data driven B2B and B2C solutions provider utilizing artificial intelligence with lead generation, automation, and analytics. TDS provides its clients with world class data with the aim of becoming a one-stop-shop for all things data. Reuters, Vodafone, Revolut, Honda and American Express are just a few of the companies they have worked with.  The next stage of development for TDS is within North America, where they are already making inroads into the real estate and capital markets sectors, offering services including business intelligence and research, demographic, market data and public data. TDS is also examining several complimentary acquisitions in Europe and in the United States and sees the potential acquisitions as a defined path for the combined companies in the years to come; hence, TDS is poised to increase its organic revenue substantially in the coming 12 months. 

The basis of the proposed transaction is for Argentum 47 Inc. to acquire 100% of The Data Source (UK) Limited by way of management relinquishing their personal right, title and interest in (i) 40,000,000 shares of Argentum’s issued and outstanding Series “B” Preferred Stock, (ii) 4,378,888 shares of Argentum’s issued and outstanding Series “C” Preferred Stock and (iii) 21,500,000 shares of Argentum’s issued and outstanding Common Stock, which shares of Series B and C Preferred Stock and Common Stock constitute precisely 51% of the voting stock of Argentum on fully diluted and converted basis (“Control Block”). Additional shares of Argentum 47, Inc. Common Stock will be issued to the TDS shareholders post-closing. Management of Argentum 47, Inc. expects to close the acquisition of The Data Source (UK) Limited in April 2022. 

Mr. Peter Smith, sole Director of Argentum 47, Inc., said: “This has been a long road for us at Argentum and I know it has been a long road for many of our shareholders too. This agreement with TDS is a major milestone for the Company and all of its shareholders, as the agreement sees TDS become the controlling element of the Company with a new and exciting direction. TDS has many blue chip clients and a phenomenal amount of activity within the artificial intelligence sector.  They are a well managed company with a seasoned board of high profile people. We have been very impressed with TDS from the outset and look forward to supporting them through this exciting transaction.” 

For more on ARGQ Subscribe Right Now!

Currently trading at a low $3,381,538 market valuation ARGQ has a very favorable stock structure with 735,116,983 shares outstanding with half restricted leaving a float of just 361,890,060 free trading shares out of 950 million authorized. The Company just executed a legally binding letter of intent to acquire UK based company, The Data Source (UK) Limited, a data driven B2B and B2C solutions provider utilizing artificial intelligence with lead generation, automation, and analytics. With offices in London, UK, the Data Source is currently honing in on the North America, where they are already making inroads into the real estate and capital markets sectors, offering services including business intelligence and research, demographic, market data and public data. The Data Source already has an established customer base in the UK including American Express, Bacardi, Vodafone, Money Super Market and Revolt. ARGQ is currently under heavy accumulation, has momentum, significant liquidity, and legions of new shareholders bidding the price higher looking for the $0.016 break and a TSNP style reverse merger move. We will be updating on ARGQ when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with ARGQ.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in ARGQ either long or short and we have not been compensated for this article

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum

Published

on

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc. chose a lead candidate.

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.

GAMMABODY™ PLATFORM

LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.

To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.

In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.

As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates. 

The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.

Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.

Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.

In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.

We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Continue Reading

Featured

Reunion Neuroscience Inc.’s (NASDAQ: REUN) Take-Private Agreement and Its Impact on Mental Health Solutions

Published

on

Reunion Neuroscience (NASDAQ: REUN) shares jump 119% as they announce an exciting new development.

Reunion Neuroscience (NASDAQ: REUN) shares jump 119% as they announce an exciting new development. The clinical-stage biopharmaceutical company has entered into a take-private transaction with MPM BioImpact, representing a significant milestone for Reunion Neuroscience. The transaction is valued at $13.1 million, a 43.1% premium to Reunion’s common shares’ 30-day volume-weighted average price.

Going private is a significant step for Reunion Neuroscience, as it means that a sizeable private-equity group or consortium of private-equity firms will purchase or acquire the stock of the publicly traded corporation.

To Discover the Inside Scoop on REUN, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Under the terms of the Arrangement Agreement, all holders of outstanding common shares of Reunion will be entitled to receive $1.12 in cash for each share held immediately before the effective time of the Arrangement. However, the agreement’s closing is subject to several conditions, which must be met before the transaction can be completed.

Hostile takeover?

While management and the board think it is a significant milestone achieved, others think differently – an investor rights law firm, Halper Sadeh LLC, is currently investigating it… The sale of Reunion Neuroscience to affiliates of MPM BioImpact for $1.12 per share in cash is currently being investigated by Halper Sadeh LLC.

The investigation concerns whether Reunion and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Reunion shareholders; (2) determine whether MPM is underpaying for Reunion; and (3) disclose all material information necessary for Reunion shareholders to assess and value the merger consideration adequately. On behalf of Reunion shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Reunion Neuroscience’s stock performance has been relatively volatile in recent years. The stock’s median target price, according to analysts’ forecasts, is $5.00, but there is a wide range of estimates, with a high of $20.00 and a low of $0.73. The current consensus among polled investment analysts is to buy $REUN stock. However, they’re a pre-revenue clinical-stage biopharmaceutical company, which means the last earnings reported a loss in the current quarter’s earnings per share – they’ve yet to generate any significant revenue. Until recently, shareholders experienced a significant decline in the stock’s value this year and were down ~54%  prior to the acquisition. There are ~9M shares in the float, with ~28% and ~13% held by insiders and institutional investors, respectively.

Overall, investors should carefully consider the potential risks and rewards associated with investing in Reunion Neuroscience, considering the wide range of price estimates and the company’s current financial performance. Thorough research and the advice of a financial professional are recommended before making any investment decisions.

We will update you on REUN when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gerd Altmann from Pixabay

Continue Reading

Featured

Marker Therapeutics, Inc. (NASDAQ: MRKR) Unveils Exciting Pre-Clinical Findings of MT-601 T Cell Therapy in Lymphoma Cells

Published

on

Marker Therapeutics, Inc. (Nasdaq: MRKR) shares surged by 45% as the company released positive pre-clinical Data on one of its candidates, MT-601.

Marker Therapeutics, Inc. (Nasdaq: MRKR) shares surged by 45% as the company released positive pre-clinical Data on one of its candidates, MT-601. They tested it on lymphoma cells in the lab, and the results showed that MT-601 can kill lymphoma cells resistant to another treatment called CD19 CAR T therapy, which is fascinating news considering many patients who receive CD19 CAR T therapy still experience a relapse within a year. 

“We have recently developed a long-term in vitro model to monitor the interaction of T cells with cancerous cells. Data from a lymphoma cell line utilizing this model demonstrated that MT-601 inhibited the growth of lymphoma cells as well as the growth of CD19 CAR-resistant lymphoma cells,” said Eric A. Smith, Ph.D., Director of Research and Development at Marker Therapeutics. Marker has posted further details about this preclinical study on the Investor Relations section of its website.

Dr. Smith continued, “Specifically, we have developed an in vitro model which reproduces the CD19 antigen-negative tumor that causes relapse and observed the following:

To Discover the Inside Scoop on MRKR, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

In this in vitro model, 98% of lymphoma cells were eliminated after a CD19-targeting CAR T cell product was administered.

While the CAR T cells significantly controlled lymphoma cell growth, we observed that three weeks after the start of anti-CD19 CAR T cell administration, a population of lymphoma cells resistant to CD19 CAR T cell administration started to grow.

These CD19 CAR-resistant lymphoma cells were tested for CD19 expression. They were shown to be negative for the CD19 surface antigen, which explained why they were no longer controlled with a second administration of anti-C19 CAR T cells, thus recapitulating the antigen-negative relapse observations in CAR relapsed/refractory lymphoma patients.

However, when MT-601, with its broad antigen recognition (Survivin, NY-ESO-1, WT-1, PRAME, MAGE-A4, SSX2), was added to this anti-CD19 CAR T cell resistant cell population, complete growth inhibition was observed.

These data highlight that MT-601 can potentially eliminate CD19 CAR T cell refractory tumors, indicating that MT-601 might offer a viable therapeutic option for lymphoma patients that have relapsed from previous CAR T cell interventions.”

MT-601 targets multiple substances on cancer cells and may provide longer-lasting results than CD19 CAR T therapy. Marker Therapeutics has started a clinical trial to test MT-601 on lymphoma patients who have relapsed after CD19 CAR T therapy or cannot receive it. The early lab results showed that MT-601 could inhibit the growth of lymphoma cells, including those resistant to CD19 CAR T therapy. The initial results have shown remarkable promise, and the team is thrilled to advance the testing of MT-601 in further clinical trials to evaluate its effectiveness and safety.

About Marker Therapeutics, Inc.

Marker Therapeutics is a company currently in the advanced stages of clinical research for developing innovative treatments in immuno-oncology. Their primary focus is on creating next-generation immunotherapies that utilize T cells, a type of immune cell, to target and fight against hematological malignancies (cancers of the blood, such as leukemia and lymphoma) and solid tumors (cancers that form in tissues or organs). These therapies aim to harness the immune system’s power to specifically recognize and eliminate cancer cells, offering potential new treatment options for patients with these types of cancers.

Capital structure

Marker Therapeutics has an outstanding total of 8.8M shares and presents a relatively small float of 6.64M shares available for public trading. Insiders hold approximately 12.82% of the shares, while institutional investors hold around 22.63%. Examining their trading history, the average volume typically hovers around 100,000 shares. In light of the positive news today, the trading activity trended much higher, with an impressive 27M shares traded at time of writing. This translates to a 270-fold increase compared to their average volume, also 4x their float.

It is essential to recognize the high volatility and rapid movements associated with Marker Therapeutics’ stock, primarily driven by the limited availability of shares. Such stocks tend to attract the interest of day and swing traders, given their propensity for swift gains or losses based on trading strategies. As evidence, a single positive news catalyst in the biotech sector can trigger a substantial surge in stock price and exponentially increase trading volume to unprecedented levels.

We will update you on MRKR when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by PDPics from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.